Literature DB >> 19020265

Men's health, low testosterone, and diabetes: individualized treatment and a multidisciplinary approach.

Donna Rice1, Robert E Brannigan2, R Keith Campbell3, Shari Fine4, Leonard Jack5, Joseph B Nelson6, Janet Regan-Klich7.   

Abstract

Testosterone plays a critical role in male reproductive and metabolic functioning. Serum testosterone levels decrease with age, and low testosterone is associated with a variety of comorbidities, including insulin resistance, type 2 diabetes, obesity, metabolic syndrome, and cardiovascular disease. Men with type 2 diabetes have been shown to have significantly lower testosterone levels than men without diabetes. Several forms of testosterone replacement therapy (eg, oral, injectable, buccal, transdermal preparations) are available for use in the United States. The primary goals of testosterone therapy are to restore physiologic testosterone levels and reduce the symptoms of hypogonadism. Testosterone therapy may be a viable option in some men with diabetes and low testosterone; however, clinicians must be aware of contraindications to therapy (eg, prostate cancer and male breast cancer), implement appropriate monitoring procedures, and ensure that patient expectations are realistic regarding treatment outcome. Data suggest that testosterone therapy may have a positive effect on bones, muscles, erythropoiesis and anemia, libido, mood and cognition, penile erection, cholesterol, fasting blood glucose, glycated hemoglobin, insulin resistance, visceral adiposity, and quality of life. Sexual health may be a window into men's health; thus, more effective communication strategies are needed between clinicians and men with diabetes to ensure that sexual health topics are adequately addressed. Diabetes educators can play a key role in screening for low testosterone, providing relevant information to patients, and increasing clinician awareness of the need to address men's sexual health and implement appropriate strategies. Multidisciplinary care and individualized treatment are needed to optimize outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020265     DOI: 10.1177/0145721708327143

Source DB:  PubMed          Journal:  Diabetes Educ        ISSN: 0145-7217            Impact factor:   2.140


  7 in total

1.  Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database.

Authors:  Louise A Brinton; J Daniel Carreon; Gretchen L Gierach; Katherine A McGlynn; Gloria Gridley
Journal:  Breast Cancer Res Treat       Date:  2009-03-29       Impact factor: 4.872

2.  Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults.

Authors:  Peter T Campbell; Christina C Newton; Alpa V Patel; Eric J Jacobs; Susan M Gapstur
Journal:  Diabetes Care       Date:  2012-06-14       Impact factor: 19.112

3.  High-normal Glucose Levels in Non-diabetic and Pre-diabetic Men Are Associated with Decreased Testosterone Levels.

Authors:  Jin Young Shin; Eun Ki Park; Byoung Jin Park; Jae Yong Shim; Hye Ree Lee
Journal:  Korean J Fam Med       Date:  2012-05-24

4.  Validity and reliability of male andropause symptoms self-assessment questionnaire among elderly males in Khuzestan province of Iran.

Authors:  Abdolrahim Asadollahi; Laleh Fani Saberi; Nasrin Faraji
Journal:  J Midlife Health       Date:  2013-10

5.  Male Sexual Dysfunction, Leptin, Pituitary and Gonadal Hormones in Nigerian Males with Metabolic Syndrome and Type 2 Diabetes Mellitus.

Authors:  Unyime Aniekpon Fabian; Mabel Ayebatonyo Charles-Davies; Adesoji Adedipe Fasanmade; John Ayodele Olaniyi; Oyediran Emmanuel Oyewole; Mayowa Ojo Owolabi; Jane Roli Adebusuyi; Olufunke Olayemi Hassan; Babatunde Mohammed Ajobo; Maria Onomhaguan Ebesunun; Kehinde Adigun; Kehinde Sola Akinlade; Olatubosun Ganiyu Arinola; Emmanuel Oluyemi Agbedana
Journal:  J Reprod Infertil       Date:  2016 Jan-Mar

6.  Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results.

Authors:  Louise A Brinton; Michael B Cook; Valerie McCormack; Kenneth C Johnson; Håkan Olsson; John T Casagrande; Rosie Cooke; Roni T Falk; Susan M Gapstur; Mia M Gaudet; J Michael Gaziano; Georgios Gkiokas; Pascal Guénel; Brian E Henderson; Albert Hollenbeck; Ann W Hsing; Laurence N Kolonel; Claudine Isaacs; Jay H Lubin; Karin B Michels; Eva Negri; Dominick Parisi; Eleni Th Petridou; Malcolm C Pike; Elio Riboli; Howard D Sesso; Kirk Snyder; Anthony J Swerdlow; Dimitrios Trichopoulos; Giske Ursin; Piet A van den Brandt; Stephen K Van Den Eeden; Elisabete Weiderpass; Walter C Willett; Marianne Ewertz; David B Thomas
Journal:  J Natl Cancer Inst       Date:  2014-02-19       Impact factor: 13.506

7.  Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).

Authors:  Rajib K Bhattacharya; Mohit Khera; Gary Blick; Harvey Kushner; Martin M Miner
Journal:  Clin Interv Aging       Date:  2012-08-24       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.